IL1R2 encodes interleukin-1 receptor type 2, a non-signaling decoy receptor that dampens IL-1 pathway activity by sequestering IL-1 ligands and limiting productive signaling through IL1R1.[1][2][3] IL1R2 exists as both membrane-bound and soluble forms, enabling local and systemic control of inflammatory amplitude.[1:1][4]
In neurodegeneration, IL1R2 is best interpreted as a regulatory brake within broader neuroinflammatory circuits rather than a stand-alone disease driver. This is relevant to disorders where chronic innate immune activation contributes to progression, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.[5][6]
Unlike IL1R1, IL1R2 lacks a functional intracellular Toll/IL-1 receptor signaling domain and therefore does not propagate canonical pro-inflammatory signaling. Instead, IL1R2 reduces IL-1 bioavailability and signaling efficiency through ligand trapping and receptor-level interference.[1:2][2:1]
Shedding and alternative processing generate soluble IL1R2, which can neutralize extracellular IL-1 and act as a distributed anti-inflammatory buffer.[3:1][4:1]
IL1R2 is enriched in myeloid compartments, where it helps determine whether IL-1 signaling resolves or escalates.[2:2][4:2] In the CNS, this logic maps to microglia-astrocyte inflammatory crosstalk, though direct cell-state atlases for IL1R2 in human neurodegeneration are still limited.[5:1][6:1]
IL-1 axis overactivation, inflammasome signaling, and sustained cytokine tone are recurrent findings in AD biology.[5:2][6:2] IL1R2 is therefore mechanistically relevant as an endogenous counter-regulator that may constrain excessive IL-1 signaling when induced.
In PD and atypical parkinsonism, inflammatory stress and microglial priming can worsen neuronal vulnerability.[6:3] Within this framework, IL1R2 is a plausible resilience node: higher decoy capacity may reduce harmful IL-1 exposure, while inadequate IL1R2 response could permit persistent inflammatory amplification.
IL1R2 (membrane or soluble) may be useful as part of a panel biomarker for inflammatory set-point, especially when paired with IL-1 pathway, inflammasome, and glial activation markers.[7:1][8:1]
Potential strategies include:
These concepts remain investigational and require disease-stage and compartment-aware validation.
Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science. 1993. ↩︎ ↩︎ ↩︎
Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 2001. ↩︎ ↩︎ ↩︎
Molgora M, Barajon I, Mantovani A, Garlanda C. Regulation of the IL-1 system by IL-1R2 and IL-1R8 in disease. Front Immunol. 2022. ↩︎ ↩︎
Orlando A, Cazzetta V, Pucino V, et al. Negative regulator IL-1R2 and its roles in immune regulation. Int J Mol Sci. 2024. ↩︎ ↩︎ ↩︎
Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2021. ↩︎ ↩︎ ↩︎
Zhou Y, Ulland TK, Colonna M. Microglia and neuroinflammation in neurodegenerative disease. Annu Rev Pathol. 2022. ↩︎ ↩︎ ↩︎ ↩︎
Berton M, Cani C, Milani G, et al. Monocyte-macrophage membrane IL-1R2 expression as a severity biomarker in sepsis. Crit Care. 2025. ↩︎ ↩︎
Vannucchi A, Croci S, Dell'Oro V, et al. Structural and dynamic properties of IL-1 receptors. Cytokine Growth Factor Rev. 2025. ↩︎ ↩︎